Seven and Eight Biopharmaceuticals Inc. is a biopharmaceutical company devoted to the discovery and development of new targeted cancer immunotherapies. We are the leaders in dendritic cell reprogramming therapies, working with TLR7/8 to activate innate immunity and generate adaptive immune responses.
Established in 2012, Seven and Eight Biopharmaceuticals Inc. was founded with exclusive insight from Dr. Yongjun Li. A proprietary pipeline of novel cancer drug candidates on TLR7/8 was produced, along with a proprietary drug conjugation technology platform.
We have demonstrated in combination and by conjugation that our TLR7/8 molecules can significantly increase the efficiency of multiple therapeutic antibodies. These antibodies include PD1/PDL1 and CTLA4, and target therapies such as Her2, CD20, EGFR, and selected chemotherapies in preclinical models.
Seven and Eight Biopharmaceuticals Inc. started its clinical program in the fall of 2017 and has completed preclinical animal studies in China, under the leadership of Dr. Lixin Li. Our investors include the 2nd largest semiconductor company in Taiwan, UMC Ventures, as well as other companies such as Yun Feng Capital, Fidelity Asia Ventures, Wuxi Ventures, Cenova Capital.
Our Focus: The primary objective of Seven and Eight Biopharmaceuticals Inc. is to develop a pipeline of proprietary novel IO drugs to combine with PD1/PDL with a substantial differentiation strategy. We have already formulated a three-tier strategy based on our proprietary TLR7/8 technologies, which are first in class systematic delivery, best in local class delivery, and target delivery through antibody-drug conjugation.